# A Study of the Safety and Effectiveness of Eltrombopag in Combination With Immunosuppressive Therapy (IST) in Korean Pediatric Patients With Treatment Naïve Severe Aplastic Anemia

> **NCT07415083** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 13 (actual)

## Conditions studied

- Aplastic Anemia

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07415083
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-21
- **Primary completion:** 2025-02-25
- **Final completion:** 2025-02-25
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2026-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07415083

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07415083, "A Study of the Safety and Effectiveness of Eltrombopag in Combination With Immunosuppressive Therapy (IST) in Korean Pediatric Patients With Treatment Naïve Severe Aplastic Anemia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07415083. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*